Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;14(6):e007975.
doi: 10.1161/CIRCHEARTFAILURE.120.007975. Epub 2021 Jun 15.

Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop

Jane A Leopold #  1 , Steven M Kawut #  2 , Micheala A Aldred  3 , Stephen L Archer  4 , Ray L Benza  5 , Michael R Bristow  6 , Evan L Brittain  7 , Naomi Chesler  8 , Frances S DeMan  9 , Serpil C Erzurum  10 , Mark T Gladwin  11 , Paul M Hassoun  12 , Anna R Hemnes  13 , Tim Lahm  3 , Joao A C Lima  13 , Joseph Loscalzo  1 , Bradley A Maron  14 , Laura Mercer Rosa  15 , John H Newman  13 , Susan Redline  16 , Stuart Rich  17 , Franz Rischard  18 , Lissa Sugeng  19 , W H Wilson Tang  20 , Ryan J Tedford  21 , Emily J Tsai  22 , Corey E Ventetuolo  23 , YouYang Zhou  24 , Neil R Aggarwal  25 , Lei Xiao  25
Affiliations
Review

Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop

Jane A Leopold et al. Circ Heart Fail. 2021 Jun.

Erratum in

Abstract

Right ventricular dysfunction is a hallmark of advanced pulmonary vascular, lung parenchymal, and left heart disease, yet the underlying mechanisms that govern (mal)adaptation remain incompletely characterized. Owing to the knowledge gaps in our understanding of the right ventricle (RV) in health and disease, the National Heart, Lung, and Blood Institute (NHLBI) commissioned a working group to identify current challenges in the field. These included a need to define and standardize normal RV structure and function in populations; access to RV tissue for research purposes and the development of complex experimental platforms that recapitulate the in vivo environment; and the advancement of imaging and invasive methodologies to study the RV within basic, translational, and clinical research programs. Specific recommendations were provided, including a call to incorporate precision medicine and innovations in prognosis, diagnosis, and novel RV therapeutics for patients with pulmonary vascular disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement Dr. Aggarwal has nothing to disclose. Dr. Aldred reports grants from NHLBI during the conduct of the study. Dr. Archer has nothing to disclose. Dr. Benza reports grants from Abbott during the conduct of the study; grants from Actelion, grants from United Therapeutics, grants from Bayer, grants from NIH/NHLBI outside the submitted work. Dr. Bristow has nothing to disclose. Dr. Brittain has nothing to disclose. Dr. Chesler reports personal fees from Endotronix, Inc. and personal fees from Aria CV outside the submitted work. Dr. de Man has nothing to disclose. Dr. Erzurum has nothing to disclose. Dr. Gladwin is a co-inventor of patents and patent applications directed to the use of recombinant neuroglobin and heme-based molecules as antidotes for CO poisoning, which have been licensed by Globin Solutions, Inc. Dr. Gladwin is a shareholder, advisor, and director in Globin Solutions, Inc. Dr. Gladwin is also co-inventor on patents directed to the use of nitrite salts in cardiovascular diseases, which were previously licensed to United Therapeutics, and is now licensed to Globin Solutions and Hope Pharmaceuticals. Dr. Gladwin is a principal investigator in a research collaboration with Bayer Pharmaceuticals to evaluate riociguat as a treatment for patients with SCD. Dr. Gladwin has served as a consultant for Epizyme, Inc., Actelion Clinical Research, Inc., Acceleron Pharma, Inc., Catalyst Biosciences, Inc., Modus Therapeutics, Sujana Biotech, LLC, Complexa Inc., Pfizer Inc., and United Therapeutics Corporation. Dr. Gladwin is also on Bayer HealthCare LLC’s Heart and Vascular Disease Research Advisory Board. Dr. Hemnes reports personal fees from Actelion, personal fees from Bayer, personal fees from Complexa, personal fees from United Therapeutics, other from PHPrecisionMed, outside the submitted work. Dr. Hassoun has served on an advisory board for Merck in 2019. Dr. Kawut reports grants from NIH, non-financial support from the ATS, and grants from Actelion, United Therapeutics, Gilead, Lung Biotech, Bayer, and Mallinkrodt to the Perelman School of Medicine for CME courses. Dr. Kawut reports grants and non-financial support from Cardiovascular Medical Research and Education Fund and non-financial support from Pulmonary Hypertension Association. Dr. Kawut has served in an advisory capacity (for grant review and other purposes) for United Therapeutics, Glaxo SmithKline, and Complexa, Inc. without financial support or in-kind benefits. Dr. Lahm reports personal fees from Bayer, personal fees from Gilead, personal fees from Actelion, other from Eli Lilly outside the submitted work. Dr. Leopold has nothing to disclose. Dr. Lima has nothing to disclose. Dr. Loscalzo is a scientific co-founder of Scipher, a startup company that uses network concepts to explore human disease treatment strategies. Dr. Maron reports other from Actelion Pharmaceuticals Inc., outside the submitted work. In addition, Dr. Maron has a patent U.S. Patent #9,605,047 issued, a patent U.S. Provisional Application ID: 62475955 pending, a patent U.S. Provisional Application Cover Sheet ID: 24624 pending, and a patent U.S. Patent application PCT/US2019/059890 pending. Dr. Mercer-Rosa has nothing to disclose. Dr. Newman has nothing to disclose. Dr. Redline reports grants and personal fees from Jazz Pharmaceuticals, personal fees from RespirCardia Inc. outside the submitted work. Dr. Rich has nothing to disclose. Dr. Rischard has nothing to disclose. Dr. Sugeng has nothing to disclose. Dr. Tang reports grants from National Institutes of Health, personal fees from Sequana Medical Inc, personal fees from Springer, personal fees from MyoKardia Inc outside the submitted work. Dr Tedford reports other from Actelion, other from Merck, personal fees from United Therapeutics, personal fees from Aria CV, personal fees from Arena pharmaceuticals, personal fees from Gradient, personal fees from Eidos Therapeutics, personal fees and other from Abbott, personal fees and other from Medtronic, personal fees from Itamar, other from Abiomed, and personal fees and other from Acceleron outside the submitted work. Dr. Tsai reports grants from National Heart, Lung, and Blood Institute (NHLBI), grants from American College of Cardiology, grants from The Rachel and Drew Katz Foundation outside the submitted work. In addition, Dr. Tsai has a patent Pharmacologic Treatment for Right Ventricular Failure (USSN 62/836,315) issued to The Trustees of Columbia University in the City of New York. Dr. Ventetuolo reports grants from NHLBI during the conduct of the study; grants from United Therapeutics, grants from American Thoracic Society, personal fees from Acceleron Pharma, personal fees from Bayer outside the submitted work. Dr. Lei Xiao has no conflict of interest to disclose. Dr. Zhao has nothing to disclose.

Figures

Figure.
Figure.
Right Ventricular Investigation: From Phenotype to Therapy
See this image and copyright information in PMC

References

    1. Mulchrone A, Bellofiore A, Douwes JM, Duong N, Beshish AG, Barton GP, Francois CJ, Eldridge MW, Goss KN and Chesler NC. Impaired right ventricular-vascular coupling in young adults born preterm. Am J Respir Crit Care Med. 2020;201:615–618. - PMC - PubMed
    1. Kawut SM, Lima JA, Barr RG, Chahal H, Jain A, Tandri H, Praestgaard A, Bagiella E, Kizer JR, Johnson WC, et al.Sex and race differences in right ventricular structure and function: the multi-ethnic study of atherosclerosis-right ventricle study. Circulation. 2011;123:2542–51. - PMC - PubMed
    1. Lewandowski AJ, Lamata P, Francis JM, Piechnik SK, Ferreira VM, Boardman H, Neubauer S, Singhal A, Leeson P and Lucas A. Breast milk consumption in preterm neonates and cardiac shape in adulthood. Pediatrics. 2016;138:e20160050. - PMC - PubMed
    1. Leary PJ, Kaufman JD, Barr RG, Bluemke DA, Curl CL, Hough CL, Lima JA, Szpiro AA, Van Hee VC and Kawut SM. Traffic-related air pollution and the right ventricle. The Multi-Ethnic Study of Atherosclerosis. Am J Respir Crit Care Med. 2014;189:1093–100. - PMC - PubMed
    1. Tedford RJ, Mudd JO, Girgis RE, Mathai SC, Zaiman AL, Housten-Harris T, Boyce D, Kelemen BW, Bacher AC, Shah AA, et al.Right ventricular dysfunction in systemic sclerosis-associated pulmonary arterial hypertension. Circ Heart Fail. 2013;6:953–63. - PMC - PubMed

Publication types

MeSH terms